Gubra A/S Asset Resilience Ratio
Gubra A/S asset resilience ratio. Gubra A/S (GUBRA) has an Asset Resilience Ratio of 79.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GUBRA cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Gubra A/S (2023–2025)
Asset resilience ratio of Gubra A/S from 2023 to 2025. This chart shows how Gubra A/S's Asset Resilience Ratio has changed over time. Read GUBRA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Gubra A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Gubra A/S balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr1.05 Billion | 79.61% |
| Total Liquid Assets | Dkr1.05 Billion | 79.61% |
Asset Resilience Insights
- Very High Liquidity: Gubra A/S maintains exceptional liquid asset reserves at 79.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Gubra A/S Industry Peers by Asset Resilience Ratio
Compare Gubra A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Gubra A/S Asset Resilience Ratio by Year (2023–2025)
Gubra A/S asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Gubra A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 79.61% | Dkr1.05 Billion ≈ $164.40 Million |
Dkr1.32 Billion ≈ $206.50 Million |
+32.62pp |
| 2024-12-31 | 47.00% | Dkr287.84 Million ≈ $45.03 Million |
Dkr612.48 Million ≈ $95.83 Million |
-17.61pp |
| 2023-12-31 | 64.61% | Dkr403.99 Million ≈ $63.21 Million |
Dkr625.28 Million ≈ $97.83 Million |
-- |
About Gubra A/S
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for th… Read more